hcc: use of lenvatinib and sorafenib
Published 5 years ago • 3.6K plays • Length 6:51Download video MP4
Download video MP3
Similar videos
-
1:22
dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
-
6:02
hcc: considerations in first-line use of sorafenib
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
1:41
dr. armaghany on frontline sorafenib versus lenvatinib in unresectable hcc
-
5:40
sorafenib initiation after tace in hcc
-
1:22
dr. cheng on phase iii findings of lenvatinib in hcc
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
7:24
practical considerations for using lenvatinib in hcc
-
8:55
implication of upfront lenvatinib in hcc
-
8:10
dosing strategies with sorafenib in hcc
-
7:37
lenvatinib as up-front therapy for unresectable hcc
-
2:56
dr. finn on role of lenvatinib in hcc treatment paradigm
-
1:38
dr. finn on significance of phase iii findings of lenvatinib in hcc
-
1:33
adverse events inform treatment decisions in hcc for frontline lenvatinib versus sorafenib
-
4:16
frontline therapy for hcc: optimizing treatment selection
-
1:02
dr. kudo discusses tace plus sorafenib in hcc
-
2:12
hepatocellular carcinoma: immunotherapy after sorafenib
-
4:35
hcc treatment: sorafenib tace